Business Context and Reporting Period
This Form 8-K was filed by Aerpio Pharmaceuticals, Inc. on April 10, 2019. The filing serves as a Regulation FD disclosure to furnish a corporate presentation (Exhibit 99.1) intended for use in investor meetings. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this specific filing. The primary event is the release of the corporate presentation referenced in Item 7.01.
Guidance, Outlook, and Risks
Management commentary, guidance, and specific risk factors are contained within the attached corporate presentation (Exhibit 99.1), which is not included in the provided text. The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the contents of the corporate presentation (Exhibit 99.1) available on the company's investor relations website at http://aerpio.com.
- Confirm that the presentation is not legally considered "filed" with the SEC for liability purposes under Section 18.
- Note the discrepancy between the request metadata (Whitehawk Therapeutics) and the filing registrant (Aerpio Pharmaceuticals, Inc.).